Fennec Pharmaceuticals (FENC) EPS (Weighted Average and Diluted) (2010 - 2025)
Fennec Pharmaceuticals posted quarterly EPS (Weighted Average and Diluted) of -$0.16 for Q4 2025, down 100.0% year-on-year from $360288.0 billion in Q4 2024, and down 700.0% on a QoQ basis from -$0.02 in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.16 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 100.0% year-over-year to -$0.16; the trailing twelve-month figure through Dec 2025 stood at -$0.33 (down 312.5% YoY), and the FY2025 full-year result was -$0.34, down 1600.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.16, down from -$0.02 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.41 in Q1 2024 and bottomed at -$0.31 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.16 (2025), against an average of -$0.13.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 278.26% in 2024, while the deepest fall reached 200.0% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.17 in 2021, then slumped by 47.06% to -$0.25 in 2022, then soared by 60.0% to -$0.1 in 2023, then advanced by 20.0% to -$0.08 in 2024, then tumbled by 100.0% to -$0.16 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.16 (Q4 2025), -$0.02 (Q3 2025), and -$0.11 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | -0.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.16 |
| Sep 30, 2025 | -0.02 |
| Jun 30, 2025 | -0.11 |
| Mar 31, 2025 | -0.04 |
| Dec 31, 2024 | -0.08 |
| Sep 30, 2024 | -0.21 |
| Jun 30, 2024 | -0.20 |
| Mar 31, 2024 | 0.41 |
| Dec 31, 2023 | -0.10 |
| Sep 30, 2023 | -0.07 |
| Jun 30, 2023 | -0.21 |
| Mar 31, 2023 | -0.23 |
| Dec 31, 2022 | -0.25 |
| Sep 30, 2022 | -0.31 |
| Jun 30, 2022 | -0.19 |
| Mar 31, 2022 | -0.14 |
| Dec 31, 2021 | -0.17 |
| Sep 30, 2021 | -0.16 |
| Jun 30, 2021 | -0.15 |
| Mar 31, 2021 | -0.18 |
| Dec 31, 2020 | -0.12 |
| Sep 30, 2020 | -0.24 |
| Jun 30, 2020 | -0.21 |
| Mar 31, 2020 | -0.19 |
| Sep 30, 2019 | -0.09 |
| Jun 30, 2019 | -0.24 |
| Mar 31, 2019 | 0.14 |
| Sep 30, 2018 | -0.14 |
| Jun 30, 2018 | -0.14 |
| Mar 31, 2018 | -0.09 |
| Sep 30, 2017 | -0.15 |
| Jun 30, 2017 | -0.11 |
| Mar 31, 2017 | -0.06 |
| Sep 30, 2016 | -0.04 |
| Jun 30, 2016 | -0.06 |
| Mar 31, 2016 | -0.04 |
| Sep 30, 2015 | -0.01 |
| Jun 30, 2015 | -0.02 |
| Mar 31, 2015 | 0.01 |
| Dec 31, 2014 | 0.14 |
| Sep 30, 2014 | 0.03 |
| Jun 30, 2014 | -0.08 |
| Mar 31, 2014 | -0.33 |
| Dec 31, 2013 | -0.04 |
| Sep 30, 2013 | -0.01 |
| Jun 30, 2013 | -0.04 |
| Mar 31, 2013 | -0.02 |
| Dec 31, 2012 | -0.04 |
| Sep 30, 2012 | -0.02 |
| Jun 30, 2012 | -49.57 |
| Mar 31, 2012 | 0.11 |
| Dec 31, 2011 | -36.92 |
| Sep 30, 2011 | -0.04 |
| Jun 30, 2011 | -0.02 |
| Mar 31, 2011 | 0.19 |
| Dec 31, 2010 | -0.05 |
| Sep 30, 2010 | -0.04 |
| Jun 30, 2010 | -0.02 |